February 7, 2018 09:03 AM EST
R&D

Sanofi sounds taps on a half dozen drug pro­grams in lat­est pipeline cleanup

John Carroll

Editor & Founder

Just 8 months af­ter Sanofi $SNY amend­ed its deal with a cash hun­gry Im­muno­Gen, pay­ing $30 mil­lion to get full com­mer­cial rights on isat­ux­imab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

FDA ap­proves Ax­some's acute mi­graine treat­ment af­ter 2022 re­jec­tion

Black­stone se­cures $1.6B so far for new life sci­ences fund tar­get­ed at $5B+

Take­da scraps pro­grams as it rais­es full-year guid­ance 

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times